Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

Weight loss drugs like Ozempic and Mounjaro could reshape food delivery habits, as users report eating smaller portions, ...

In negotiations with manufacturers, the administration aims to provide lower-dose weight-loss medications for about $149 a ...

Novo Nordisk A/S trimmed its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and ...

Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.

In results published on November 5, the Danish pharmaceutical group said it now expects sales growth of 8–11 per cent at constant exchange rates.